Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone269-389-2600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.60 billion
Profitability
Miscellaneous
Employees36,000
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable
Stryker (NYSE:SYK) Frequently Asked Questions
What is Stryker's stock symbol?
Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."
How often does Stryker pay dividends? What is the dividend yield for Stryker?
Stryker declared a quarterly dividend on Wednesday, February 6th. Stockholders of record on Friday, March 29th will be given a dividend of $0.52 per share on Tuesday, April 30th. This represents a $2.08 annualized dividend and a dividend yield of 1.10%. The ex-dividend date is Thursday, March 28th. View Stryker's Dividend History.
How were Stryker's earnings last quarter?
Stryker Co. (NYSE:SYK) announced its earnings results on Tuesday, January, 29th. The medical technology company reported $2.18 EPS for the quarter, beating the consensus estimate of $2.15 by $0.03. The medical technology company had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.73 billion. Stryker had a net margin of 26.12% and a return on equity of 27.60%. View Stryker's Earnings History.
When is Stryker's next earnings date?
What guidance has Stryker issued on next quarter's earnings?
Stryker updated its FY19 earnings guidance on Tuesday, January, 29th. The company provided earnings per share (EPS) guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.01. Stryker also updated its FY 2019 guidance to $8.00-8.20 EPS.
What price target have analysts set for SYK?
21 equities research analysts have issued 12 month target prices for Stryker's stock. Their forecasts range from $156.75 to $205.00. On average, they expect Stryker's share price to reach $184.6875 in the next year. This suggests that the stock has a possible downside of 2.1%. View Analyst Price Targets for Stryker.
What is the consensus analysts' recommendation for Stryker?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 7 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.
What are Wall Street analysts saying about Stryker stock?
Here are some recent quotes from research analysts about Stryker stock:
- 1. According to Zacks Investment Research, "Stryker exited the fourth quarter of 2018 on a solid note, with earnings and revenues surpassing the consensus mark. The company continues to gain from its core MedSurg unit which put up a solid show in the quarter. Additionally, strength in flagship Mako platform has consistently favored the company. Management is optimistic about the recent K2M acquisition which drove the core Neurotechnology & Spine unit in the fourth quarter. Solid international growth buoys optimism. Expansion in operating margin is a positive while a strong view for 2019 is indicative of brighter prospects. Stryker has outperformed the industry in a year. On the flip side, contraction in gross margin raises concern. Additionally, fourth-quarter revenues were impacted by unfavorable foreign currency movement. Pricing pressure also continues to plague Stryker. Stiff competition in the MedTech space is likely to mar prospects. The stock is overvalued at the moment." (2/4/2019)
- 2. Needham & Company LLC analysts commented, "We attended at its Orthopaedics facility in on 11/8/18. We highlight some of our take-aways from the event below." (11/9/2018)
Has Stryker been receiving favorable news coverage?
Press coverage about SYK stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stryker earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the medical technology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Stryker's key competitors?
Some companies that are related to Stryker include 3M (MMM), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Insulet (PODD), Novocure (NVCR) and Integra Lifesciences (IART).
What other stocks do shareholders of Stryker own?
Who are Stryker's key executives?
Stryker's management team includes the folowing people:
- Mr. Kevin A. Lobo, Chairman & CEO (Age 54)
- Mr. Timothy J. Scannell, Pres & COO (Age 54)
- Mr. Glenn S. Boehnlein, VP & CFO (Age 57)
- Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 57)
- Mr. David K. Floyd, Group Pres & Advisor to the CEO (Age 58)
Who are Stryker's major shareholders?
Stryker's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.65%), Greenleaf Trust (6.04%), Bank of New York Mellon Corp (1.96%), Massachusetts Financial Services Co. MA (1.75%), Oregon Public Employees Retirement Fund (1.62%) and Fundsmith LLP (1.47%). Company insiders that own Stryker stock include Bijoy Sagar, David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, Michael Damon Hutchinson, Roch Doliveux, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.
Which major investors are selling Stryker stock?
SYK stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Bank of New York Mellon Corp, State Treasurer State of Michigan, Greenleaf Trust, First Trust Advisors LP, Rehmann Capital Advisory Group, Fundsmith LLP and Paloma Partners Management Co. Company insiders that have sold Stryker company stock in the last year include Bijoy Sagar, David Floyd, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, Michael Damon Hutchinson, Timothy J Scannell and Yin C Becker. View Insider Buying and Selling for Stryker.
Which major investors are buying Stryker stock?
SYK stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, BlackRock Inc., GQG Partners LLC, California Public Employees Retirement System, Mackenzie Financial Corp, Two Sigma Advisers LP, Geode Capital Management LLC and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Stryker.
How do I buy shares of Stryker?
Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stryker's stock price today?
One share of SYK stock can currently be purchased for approximately $188.67.
How big of a company is Stryker?
Stryker has a market capitalization of $70.31 billion and generates $13.60 billion in revenue each year. The medical technology company earns $3.55 billion in net income (profit) each year or $7.31 on an earnings per share basis. Stryker employs 36,000 workers across the globe.
What is Stryker's official website?
How can I contact Stryker?
Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]
MarketBeat Community Rating for Stryker (NYSE SYK)
MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote "Outperform" if you believe SYK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days.
